
Updates on COVID-19 Vaccine Effectiveness during Omicron

Ruth Link-Gelles, PhD, MPH LCDR, US Public Health Service Program Lead, COVID-19 Vaccine Effectiveness National Center for Immunization and Respiratory Diseases

ACIP September 1, 2022





cdc.gov/coronavirus

Organization of presentation

Presentation organized by outcome, then by age within outcome

- Infection
- Emergency department/urgent care (ED/UC)
- Hospitalization

Vaccine effectiveness (VE) against infection with Omicron

Increasing Community Access to Testing (ICATT) Partnership: VE analysis for <u>symptomatic infection</u>

- Nationwide community-based drive-through COVID-19 testing via pharmacies
- Self-reported vaccine history at time of registration for COVID-19 testing; excluded those who did not report vaccination status
- **Design**: Test-negative, case-control analysis
- Population: Persons with ≥1 COVID-like symptom and nucleic acid amplification testing (NAAT); immunocompromised excluded


Adjusted for:

 Race, ethnicity, gender, patient state, site census tract's social vulnerability index (SVI), circulating cases of COVID-19 by zip code in the last 7 days, pharmacy partner, test date

Period for analysis:

- Tested: July 2, 2022 - August 20, 2022, BA.4/BA.5 predominant period

ICATT: mRNA 3 vs. 2-dose relative VE against <u>symptomatic</u> <u>infection</u> during BA.4/BA.5, ages 5+ years



*Vaccination dose dates are collected as month and year. Month 0 represents tests in the same month as last dose (at least 2 weeks after last dose). For all months greater than or equal to 1 the value represents the difference between calendar month of test and calendar month of last dose receipt (at least 2 weeks after last dose).

CDC preliminary unpublished data. Prior infection excluded, other methods based on: Fleming-Dutra KE, Britton A, Shang N, et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. *JAMA*. Published online May 13, 2022. doi:10.1001/jama.2022.7493

ICATT: mRNA VE against <u>symptomatic infection</u> during BA.4/BA.5, ages 50+ years


3 vs. 0-dose absolute VE 4 vs. 3-dose relative VE 100% 100% 80% 80% 50-64 years 65+ years Vaccine Effectiveness Effectiveness 95% Cls 60% 60% 40% 40% Vaccine 20% 20% 0% 0% -20% -20% 0 2 3 Λ 2 3 0 Δ *Months since last dose *Months since last dose

*Vaccination dose dates are collected as month and year. Month 0 represents tests in the same month as last dose (at least 2 weeks after last dose). For all months greater than or equal to 1 the value represents the difference between calendar month of test and calendar month of last dose receipt (at least 2 weeks after last dose).

CDC preliminary unpublished data. Prior infection excluded, other methods based on: Fleming-Dutra KE, Britton A, Shang N, et al. Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance. *JAMA*. Published online May 13, 2022. doi:10.1001/jama.2022.7493

Vaccine effectiveness against <u>emergency</u> <u>department/urgent care (ED/UC)</u> due to Omicron in the US

VISION Multi-State Network of Electronic Health Records



- Cases: COVID-like illness (CLI) with positive PCR for SARS-CoV-2 within 14 days before or 72 hours after the admission or encounter
- Controls: CLI with negative PCR for SARS-CoV-2

- Delta vs. Omicron determined by time when Omicron predominated in study site (mid-December 2021)
- VE adjusted by propensity to be vaccinated weights, calendar time, region, local virus circulation, and age
- Vaccination documented by electronic health records and state and city registries

VISION: Pfizer-BioNTech VE for <u>ED/UC</u> visits by number of doses and time since last dose receipt for children and adolescents during Omicron, mid-Dec 2021-mid-Jul 2022

Vaccination status (days since most recent dose)	Total	SARS-CoV-2 positive, N	Adjusted VE (95% CI)	2-dose VE3-dose VE
5-11 years				
Unvaccinated	21,009	1,375	Ref	
2 doses (14-59)	1,151	72	51 (34-64)	
2 doses (60-149)	4,068	179	22 (6-36)	⊢
2 doses (≥150)	1,338	109	18 (-4-35)	·
12-15 years				
Unvaccinated	7,318	1,443	Ref	
2 doses (14-59)	219	27	60 (37-74)	
2 doses (60-149)	1,082	196	42 (30-53)	
2 doses (≥150)	3,308	587	14 (2-24)	
3 doses (≥7)	973	43	63 (48-73)	·•
				-20 0 20 40 60 80 100 Vaccine Effectiveness (%)

CDC, preliminary unpublished data. Individuals with prior infections excluded. Adjusted for calendar time, geographic region, age, sex, race, ethnicity, local virus circulation, respiratory or nonrespiratory underlying medical conditions, and propensity to be vaccinated 9

COVID-like illness: included acute respiratory illness (e.g., COVID-19, respiratory failure, or pneumonia) or related signs or symptoms (cough, fever, dyspnea, vomiting, or diarrhea)

VISION: mRNA VE for <u>ED/UC visits</u> among <u>immunocompetent adults ≥18 years</u> by number of doses and time since last dose receipt, late-Mar–late-Jul 2022

Vaccination status (days since most recent dose)	Total	CLI cases	Days since most recent dose, median (IQR)	Adjusted VE % (95% Cl)	2-dose VE3-dose VE
BA.2/BA.2.12.1 period					• 4-dose VE
Unvaccinated	27,907	3,501		Ref.	
2 doses (14-149)	1,774	110	104 (71, 128)	51 (38 - 60)	⊢−−−−
2 doses (≥150)	20,883	2,584	352 (278, 398)	12 (7 - 17)	⊢ ●→
3 doses (7-119)	9,142	441	94 (72, 108)	56 (51 - 61)	⊢● −1
3 doses (≥120)	26,654	3,186	166 (145, 190)	26 (21 - 30)	⊢−
4 doses (7-59)*	4,092	355	28 (17-42)	66 (60 - 71)	⊢ ●1
BA.4/BA.5 period					
Unvaccinated	22,867	6,717		Ref.	
2 doses (14-149)	540	82	106 (70, 133)	44 (28 - 56)	·
2 doses (≥150)	15,614	3,686	420 (321, 465)	26 (22 - 30)	⊢● ⊣
3 doses (7-119)	1,280	154	77 (45, 100)	59 (50 - 66)	
3 doses (≥120)	18,803	4,063	223 (193, 252)	33 (29 - 37)	
4 doses (7-59)*	2,169	259	39 (24, 49)	62 (54 - 68)	•••••
4 doses (60-119)*	3,741	617	85 (74, 91)	49 (41 - 56)	·••
* Only estimated among	g adults ≥50	years of age			0 20 40 60 80 100

BA.2/BA.2.12.1 estimates: Link-Gelles et al. MMWR: https://www.cdc.gov/mmwr/volumes/71/wr/mm7129e1.htm

BA.4/BA.5 estimates: CDC, preliminary unpublished data. Individuals with prior infections excluded. Adjusted for calendar time, geographic region, age, sex, race, ethnicity, local virus circulation, respiratory or nor respiratory underlying medical conditions, and propensity to be vaccinated.

Vaccine Effectiveness (%)

Cosmos Multi-State Network of Electronic Health Records

- Platform: Cosmos is an opt-in database of more than 162 million patient records drawn from health care organizations using the Epic platform for electronic health records
- **Design**: test-negative, case-control analysis
- **Period:** early April 2022 through mid-August 2022
- **Population**: immunocompetent children and adolescents ages 5–15 years
- Methods:
 - Cases: COVID-like illness with <u>positive</u> SARS-CoV-2 NAAT within 14 days before or 3 days after the encounter
 - Controls: COVID-like illness with <u>negative</u> SARS-CoV-2 NAAT within 14 days before or 3 days after the encounter
 - VE estimated using unconditional logistic regression; cases and controls frequency matched by 2-week period and state
 - adjusted for race, ethnicity, sex, influenza vaccination status, number of underlying conditions

Cosmos: mRNA VE for <u>ED/UC visits</u> among <u>children and adolescents</u> by number of doses and time since last dose during Omicron predominance (combined BA.2/2.12.1/4/5 period) April 2022– mid-August 2022

Vaccination status (days since most recent dose)	Total	SARS-CoV-2 positive, N (%)	Adjusted VE % (95% CI)	 2-dose VE 3-dose VE
5-11-year-olds				
Unvaccinated	74,710	15,148 (20.3)	REF	
2 doses (14-120 days)	1,591	186 (11.7)	48 (39-55)	
2 doses (≥120 days)	3,674	679 (18.5)	11 (3-18)	⊢
3 doses (14-120 days)	195	21 (10.8)	52 (27-71)	·
12-15-year-olds				
Unvaccinated	28,722	6,022 (21)	REF	
2 doses (14-120 days)	443	37 (8)	65 (52-76)	
2 doses (≥120 days)	4,359	736 (17)	21 (14-28)	
3 doses (7-120 days)	687	64 (9)	60 (48-69)	·
3 doses (≥120 days)	524	88 (17)	18 (-3-36)	
				0 20 40 60 80 100
				Vaccine Effectiveness (%)

Vaccine effectiveness against hospitalization due to Omicron in the US

VISION: mRNA VE for <u>hospitalizations</u> among <u>immunocompetent adults ≥18 years</u> by number of doses and time since last dose receipt, late-Mar-late-Jul 2022

Vaccination status (days since most			Days since most recent	Adjusted VE	 2-dose VE 3-dose VE
recent dose)	Total	CLI cases	dose, median (IQR)	% (95% CI)	• 4-dose VE
BA.2/BA.2.12.1 period					4-dose ve
Unvaccinated	6,682	494		Ref.	
2 doses (14-149)	*	*	*	*	
2 doses (≥150)	5,118	393	371 (308, 413)	24 (12 - 35)	•••
3 doses (7-119)	2,350	72	94 (74, 108)	69 (58 - 76)	⊢
3 doses (≥120)	7,686	519	168 (146, 191)	52 (44 - 59)	
4 doses (7-59)**	1,204	74	27 (17, 41)	80 (71 - 85)	·•
BA.4/BA.5 period					
Unvaccinated	4,578	913		Ref.	
2 doses (14-149)	*	*	*	*	
2 doses (≥150)	3,592	619	445 (369 <i>,</i> 484)	25 (15 - 33)	▶ −−−1
3 doses (7-119)	335	32	76 (46, 100)	49 (20 - 68)	•
3 doses (≥120)	5,030	869	229 (199, 256)	34 (25 - 42)	⊢
4 doses (7-59)**	717	81	38 (23, 49)	60 (42 - 73)	·
4 doses (60-119)** * Estimates with confidence int	1,146 ervals >50 perc	157 centage points are	84 (73, 97) e not shown.	56 (41 - 67)	
** Only estimated among adult	s ≥50 years of a	age			0 20 40 60 80 100

BA.2/BA.2.12.1 estimates: Link-Gelles et al. MMWR: https://www.cdc.gov/mmwr/volumes/71/wr/mm7129e1.htm

Vaccine Effectiveness (%) BA.4/BA.5 estimates: CDC, preliminary unpublished data. Individuals with prior infections excluded. Adjusted for calendar time, geographic region, age, sex, race, ethnicity, local virus circulation, respiratory or nonrespiratory underlying medical conditions, and propensity to be vaccinated.


IVY Network: VE against Omicron variant COVID-19-associated hospitalization

- Design: Test-negative, case-control assessment
- **Period**: December 26, 2021–July 31, 2022
- Population: Adults (≥18 years) hospitalized at 21 medical centers in 18 states
- Participants have COVID-like illness and test:
 - <u>Cases</u>: SARS-CoV-2-<u>positive</u> by RT-PCR or antigen tests
 - <u>Controls</u>: SARS-CoV-2-<u>negative</u> by RT-PCR
- VE adjustments:
 - Age (18–49, 50–64, and ≥65 years, or continuous for models stratified by age), sex, race/ethnicity, admission date (biweekly), and HHS region





IVY Network: mRNA VE against <u>hospitalization</u> among <u>immunocompetent</u> adults during Omicron period, Dec 26, 2021–Jul 31, 2022




0 10 20 30 40 50 60 70 80 90 100 Vaccine Effectiveness (%)

2-dose VE

* Only estimated among adults ≥50 years of age

IVY Network: mRNA VE against <u>hospitalization</u> among <u>immunocompromised</u> adults during Omicron period, Dec 26, 2021–Jul 31, 2022



Vaccine Effectiveness (%)

3-dose VE



Vaccine effectiveness during Omicron

- Effectiveness against severe disease continues to be higher and more sustained over time than effectiveness against infection
- VE during BA.4/BA.5 predominance was generally comparable to VE during BA.2 predominance
- 3rd dose provides significant additional protection against infection and severe disease in all ages studied
 - VE post 3rd dose appears to wane more slowly compared with 2 doses alone during Omicron
 - Similar patterns across age groups
- Coverage with 4th dose too low to draw conclusions but additional benefits demonstrated for infection, ED/UC, and hospitalization

Acknowledgements


CDC COVID-19 Vaccine Effectiveness and Policy Team

- Tamara Pilishvili
- Sara Oliver
- Amadea Britton
- Allison Ciesla
- Monica Godfrey
- Katherine Fleming-Dutra
- Morgan Najdowski
- Lauren Roper
- Evelyn Twentyman
- Ryan Wiegand

PIs and study staff for ICATT, VISION, COSMOS, IVY

- Katherine Adams
- Levi Bonnell
- Alexandra Dalton
- Ashley Fowlkes
- Matthew Levy
- Samantha Olson
- Manish Patel
- Zach Smith
- Diya Surie
- Mark Tenforde

- Mark Thompson
- Laura Zambrano
- Joe Deckert
- Eric Barkley
- Alex Piff
- Caleb Cox
- Johnston Thayer



For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

